TME Pharma to Present NOX-A12 GLORIA Trial Results in Glioblastoma at ESMO 2024

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company, is pioneering new treatments for cancer that target the tumor microenvironment (TME). The company recently announced that findings from its NOX-A12 GLORIA Phase 1/2 trial, focusing on first-line treatment for brain cancer (glioblastoma), will be featured at the European Society for Medical Oncology (ESMO) Congress. The event is set to be held in Barcelona, Spain, from September 13 to 17, 2024.

The presentation will delve into the dual inhibition effects of NOX-A12 and bevacizumab on glioblastoma, based on data from the expansion arm of the GLORIA Phase 1/2 trial. This analysis aims to shed light on the potential benefits of this combination therapy in combating the aggressive brain cancer. The full abstract of the study will be accessible online via the ESMO Congress website, starting at 00:05 a.m. CEST on Monday, September 9, 2024. TME Pharma will also make this information available on its official website.

The title of the presentation is "Dual inhibition of postradiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial." It will be presented by Dr. Frank A. Giordano, Chair of the Department of Radiation Oncology at the University Medical Center Mannheim, Germany. This mini oral session, focusing on central nervous system tumors, is scheduled to take place from 08:30 to 08:35 a.m. CEST on Sunday, September 15, 2024.

TME Pharma is committed to developing innovative treatments for the most aggressive forms of cancer. Their oncology pipeline is strategically designed to disrupt the tumor microenvironment and cancer immunity cycle. By breaking down the barriers that protect tumors from the immune system and preventing tumor repair mechanisms, TME Pharma aims to deliver more effective cancer therapies.

This announcement highlights TME Pharma's progress in their mission to improve cancer treatment through novel scientific approaches. The upcoming presentation at the ESMO Congress represents a significant milestone in their ongoing research and development efforts.